Genomic and Transcriptomic Characterization of Advanced Pancreatic Ductal Adenocarcinoma (PDAC) May Inform Systemic Therapy

HPB - United Kingdom
doi 10.1016/j.hpb.2017.02.177
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)

International Journal of Medical Sciences
Medicine
2020English

A Thrombin-Activated PAR-1 Pathway Drives Pancreatic Ductal Adenocarcinoma (PDAC) Growth and Metastasis

Journal of Purdue Undergraduate Research
2019English

The Characterization of “Islet Invasion” in Pancreatic Ductal Adenocarcinoma

HPB
HepatologyGastroenterology
2018English

MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC)

Frontiers in Physiology
Physiology
2019English

Immunohistochemical Expression of NEDD9, E-Cadherin and Γ-Catenin and Their Prognostic Significance in Pancreatic Ductal Adenocarcinoma (PDAC)

Bosnian Journal of Basic Medical Sciences
Medicine
2018English

Can Pharmacogenomics Guide Effective Anticancer Therapy in Pancreatic Ductal Adenocarcinoma?

Pharmacogenomics
Molecular MedicineGeneticsPharmacology
2012English

Pancreatic Ductal Adenocarcinoma With Cystic Features

HPB
HepatologyGastroenterology
2016English

Features of Immunophenotype of Pancreatic Ductal Adenocarcinoma

Zaporozhye Medical Journal
2014English

Tumoral EHF Predicts the Efficacy of Anti-Pd1 Therapy in Pancreatic Ductal Adenocarcinoma

Journal of Experimental Medicine
MedicineAllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy